Biogenera participated in the Swiss Biotech Day 2025, one of Europe’s most prominent events in the biotechnology sector, held on May 5–6 at the Congress Center in Basel.
It was a strategic occasion to strengthen our international relationships, present our ongoing R&D programs, and engage in meaningful exchanges with key players in the global pharma-biotech landscape.
Institutional Presence
Biogenera was represented by Massimiliano Cesarini (CEO & Chairman) and Federico Ragni (Head of Business Development), who took part in one-to-one partnering meetings, industry roundtables, and extensive networking opportunities.
Our team introduced the progress of our proprietary MyGenera™ platform, based on anti-gene oligonucleotides using Peptide Nucleic Acid (PNA) technology, and showcased the clinical development of BGA002, the world’s first drug candidate targeting the MYCN oncogene, a key driver in aggressive pediatric and adult cancers.
Partnership and Vision
Swiss Biotech Day offered a unique opportunity to:
- Consolidate scientific and industrial partnerships
- Gather feedback from international experts
- Explore licensing and co-development opportunities
- Strengthen Biogenera’s visibility within leading European biotech ecosystems
Looking Ahead
Participating in high-level events like the Swiss Biotech Day reflects our commitment to advancing transformative science and making it accessible to those who need it most. As we approach the Phase I clinical trial of BGA002, Biogenera continues to engage with global partners to accelerate the delivery of breakthrough therapies.
English 
Italian